C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, life‐threatening hematologic disease characterized by chronic complement‐mediated hemolysis and thrombosis. Despite treatment with eculizumab, a C5 inhibitor, 72% of individuals remain anemic. Pegcetacoplan (APL‐2), a PEGylated C3 inhibitor,...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	American journal of hematology Ročník 95; číslo 11; s. 1334 - 1343
Hlavní autoři:	Castro, Carlos, Grossi, Federico, Weitz, Ilene Ceil, Maciejewski, Jaroslaw, Sharma, Vivek, Roman, Eloy, Brodsky, Robert A., Tan, Lisa, Di Casoli, Carl, El Mehdi, Delphine, Deschatelets, Pascal, Francois, Cedric
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Hoboken, USA John Wiley & Sons, Inc 01.11.2020 Wiley Subscription Services, Inc
Témata:	Adult Anemia, Hemolytic - drug therapy Anemia, Hemolytic - etiology Anemia, Hemolytic - prevention & control Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Bilirubin Bilirubin - blood Blood diseases Chemical and Drug Induced Liver Injury - etiology Complement C3 - antagonists & inhibitors Complement C5 - antagonists & inhibitors Complement component C3 Drug Substitution Female Fever - chemically induced Hematological diseases Hematology Hemoglobin Hemoglobins - analysis Hemoglobinuria, Paroxysmal - blood Hemoglobinuria, Paroxysmal - drug therapy Hemoglobinuria, Paroxysmal - immunology Hemolysis Hemolysis - drug effects Humans L-Lactate dehydrogenase L-Lactate Dehydrogenase - blood Lactic acid Male Middle Aged Monoclonal antibodies Pancreatitis - chemically induced Paroxysmal nocturnal hemoglobinuria Pharmacodynamics Pharmacokinetics Prospective Studies Reticulocyte Count Thrombosis
ISSN:	0361-8609, 1096-8652, 1096-8652
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!